3Scherer R U,Spangenberg P.Procoagulant activity in patients with isolated severe head trauma[J].Crit Care Med,1998,26:149-156.
4Bernard G R,Vincent J L,Laterre P F,et al.Efficacy and safety of recombinant human activated protein C for severe sepsis[J].N Engl J Med,2001,344:699-709.
5Toshiyuki Yano.Neuroprotective Effect of Urinary Trypsin Inhibitor against Focal Cerebral Ischemia-Repeffusion Injury in Rats.Anesthesiology,2003,98:465-473.
6Angus DC,Linde-Zwirble WT,Lidicker J,et al.Epidemiology of severe sepsis in the United States:analysis of incidence,outcome and associated costs of care.Crit Care Med,2001,29:1303-1310.
7Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis:ACCP/SCCM Consensus Conference Committee.Chest,1992,101:1644-1655.
8Marshall JC,Cook DJ,Christou NV,et al.Multiple organ dysfunction score:A reliable descriptor of a complex clinical outcome.Crit Care Med,1995,23:1638-1652.
9Dellinger RP,Carlet JM,Masur H,et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.Crit Care Med,2004,32:858 -873.
10Cronin L,Cook DJ,Carlet J,et al.Corticosteroid treatment for sepsis:a critical appraisal and meta-analysis of the literature.Crit Care Med,1995,23:1430-1439.
